- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00606021
A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin combination in patients with advanced non-squamous non-small cell lung cancer.
A total of approximately 100 patients are planned to be enrolled, and following completion of four cycles of pemetrexed-cisplatin (Induction Phase) those patients in which disease progression has not occurred will be randomized in a 2:1 ratio to one of two treatment arms (Maintenance Phase): Arm A (pemetrexed plus best supportive care) or Arm B (best supportive care alone).
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
-
Assiut, Египет, 0000
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Cairo, Египет, 11372
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Mounofia, Египет, 32514
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Beirut, Ливан
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Riyadh, Саудовская Аравия, 11211
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion criteria:
- You must be at least 18 years old
- You must have been diagnosed with non-squamous non-small cell lung cancer (NSCLC)
- You must have had no prior systemic anticancer therapy for lung cancer
- You must live close enough to the study doctor to be able to visit regularly for follow up
- You must have signed informed consent form indicating your willingness to take part in this study
- Your laboratory and medical history and tests must meet study requirements
Exclusion criteria:
- Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
- Prior radiotherapy and surgery should be completed at least 4 weeks prior to initiation of treatment
- Serious concomitant systemic disorder (e.g., active infection including human immunodeficiency virus, or unstable cardiovascular disease)
- Prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer unless treated at least 5 years previously with no subsequent evidence of recurrence
- Brain metastasis
- Presence of clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry
- Significant weight loss (greater than 10%), over the previous 6 weeks before study entry
- Concurrent administration of any other antitumor therapy
- Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam)
- Inability or unwillingness to take folic acid, dexamethasone (or equivalent) or vitamin B12 supplementation
- Pregnancy or breast-feeding
- You are allergic to pemetrexed
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: A: Pemetrexed + Best Supportive Care
Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician. |
500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
Другие имена:
Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
|
Активный компаратор: B: Best Supportive Care
Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
|
Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Progression Free Survival During Maintenance Phase
Временное ограничение: Randomization to progression of disease (PD) or date of death from any cause up to 30.9 months
|
Progression free survival is defined as the time from randomization until the date of progression of disease (PD) or death from any cause.
PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
PD is ≥20% increase in sum of longest diameter of target lesions.
PD in maintenance phase uses the last lesion assessment prior to randomization as the baseline assessment.
|
Randomization to progression of disease (PD) or date of death from any cause up to 30.9 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP])
Временное ограничение: First dose of study drug during IP to PD or date of death from any cause up to 33.6 months
|
Progression-free survival in overall period is defined as the time from the date of first dose of study drug during IP until the date of PD or death from any cause.
PD was determined using RECIST criteria.
PD is ≥20% increase in sum of longest diameter of target lesions.
PD in overall period uses the screening lesion assessment prior to the induction phase as the baseline assessment.
|
First dose of study drug during IP to PD or date of death from any cause up to 33.6 months
|
Overall Survival During Maintenance Phase
Временное ограничение: Randomization to PD or date of death from any cause up to 31.3 months
|
Overall survival in maintenance phase is defined as the time from randomization to death.
Participants who were alive were censored at the last contact.
|
Randomization to PD or date of death from any cause up to 31.3 months
|
Overall Survival During Overall Period (IP + MP)
Временное ограничение: First dose of study drug during IP to PD or date of death from any cause up to 34.1 months
|
Overall survival in overall period is defined as the time from first dose of study drug during IP to death.
Participants who were alive were censored at the last contact.
|
First dose of study drug during IP to PD or date of death from any cause up to 34.1 months
|
Number of Participants With Adverse Events (AEs) During Overall Period
Временное ограничение: First dose of study drug during IP through overall study completion (up to 34.3) months
|
The list of serious adverse events (SAEs) and other non-serious adverse events (AEs) are in Adverse Events Section.
|
First dose of study drug during IP through overall study completion (up to 34.3) months
|
Tumor Response Rate and Disease Control Rate After Induction Phase (IP)
Временное ограничение: Randomization to measured PD up to 31.4 months
|
Tumor response rate (%) is the number of responders (participants with best response of CR or PR) divided by the number of participants qualified for tumor response according to RECIST criteria multiplied by 100.
Disease control rate is percentage of participants with a best response of stable disease [SD], PR, or CR.
CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; PD is≥20% increase in sum of longest diameter of target lesions.
SD= neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
|
Randomization to measured PD up to 31.4 months
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9am to 5pm Eastern Time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Заболевания дыхательных путей
- Новообразования
- Легочные заболевания
- Новообразования по локализации
- Новообразования дыхательных путей
- Грудные новообразования
- Рак, Бронхогенный
- Бронхиальные новообразования
- Новообразования легких
- Карцинома немелкоклеточного легкого
- Молекулярные механизмы фармакологического действия
- Ингибиторы синтеза нуклеиновых кислот
- Ингибиторы ферментов
- Противоопухолевые агенты
- Антагонисты фолиевой кислоты
- Пеметрексед
Другие идентификационные номера исследования
- 11839 (DAIDS ES)
- H3E-EZ-S114 (Другой идентификатор: Eli Lilly and Company)
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .